主页 > 医学动态 >
【drug-news】四家药厂瓜分市场：卫材止吐药Alox在
TOKYO (Reuters) Mar 03 - Japan's Eisai Co Ltd said on Monday U.S. regulators had approved its injectable antiemetic Aloxi (palonosetron) to be used to prevent vomiting after surgery.
Aloxi has been on the market in the United States since 2003 to treat chemotherapy-induced nausea.
In the treatment of post-surgery nausea, Aloxi will compete with GlaxoSmithKline's Zofran and Roche's Kytril, which are now off-patent, as well as Sanofi-Aventis's Anzemet.
Eisai also said it had received approval in Japan for its Vasolan tablets to be used to treat atrial fibrillation in addition to coronary heart disease.
http://www.medscape.com/viewarticle/570927 日本卫材公司宣布，美国政府批准了其供注射用的镇吐剂Aloxi(帕洛司琼)用于术后止吐。Aloxi于2003年在美国上市，用于治疗化疗引起的恶心症状。在术后恶心的治疗上，Aloxi将与葛兰素的Zofran（昂丹司琼）和罗氏的Kytril（格拉司琼）展开竞争，二者和赛诺菲安万特的Anzemet（多拉司琼）一样，专利业已过期。
卫材公司声称，他们的Vasolan片除治疗冠心病外，还在日本获得批准用于治疗动脉纤维化。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-20 17:14
医学,生命科学网